NIAID Funding News, January 15, 2025

January 15, 2025 NIAID Funding News Read this full edition online at https://www.niaid.nih.gov/grants-contracts/funding-news?edition=2025-01-15 Feature Articles  Don't Derail Your Application: Avoid These Electronic Submission Errors Submitting your application well in advance of its receipt date will allow you ample time to validate the upload and correct any content-related upload errors. Opportunities and Resources Develop Novel Research Approaches to Target Cell Surface HIV Envelope for Cell Elimination This funding opportunity supports basic research on HIV-1 Env biology and translational research that develops or optimizes biologics. Characterize Role of Defective Proviruses in HIV Persistence NIAID is seeking research that characterizes the role of defective HIV in blood and tissue sites in people living with HIV on antiretroviral therapy. Develop Novel Therapeutics to Treat Botulinum Neurotoxin Intoxication This initiative promotes the discovery of novel, improved candidates for treating Botulinum Neurotoxin (BoNT) toxicity, as well as platforms for the intraneuronal delivery of antitoxins to reverse BoNT intoxication. Two Research Areas Comprise NIAID's 2026 Omnibus Contract Solicitation Advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases. In The News New NIH Public Access Policy Lifts Embargo Period on Manuscripts The new NIH policy mandates the submission of author-accepted manuscripts to NIH's PubMed Central without a 12-month embargo period. Help Shape the NIH Strategic Plan for Disability Health Research NIH invites feedback that will help shape the framework of the ensuing NIH Strategic Plan for Disability Health Research for Fiscal Years 2026 to 2030. News Briefs and Worth Repeating Make Sure to Use New Versions of Parent Announcements NIH Seeks Input on Use of Metadata to Increase Transparency of Research Results Updated eRA Resource Aligns Training Tables with New FORMS-I Requirements Stream NIAID's Advisory Council Meeting on January 27 Advice Corner Want to Master NIH Funding? Tune In to These Grants Podcasts Learn how to better navigate the NIH grants application and award process. Reader Questions "What is an investigational new drug and an investigational device exemption?" "Are there guidelines for the font I use in my application?" New Funding Opportunities NOT-AG-24-073, Notice of Special Interest (NOSI): Alzheimer's and Alzheimer's-Related Dementias (AD/ADRD) Focused Competitive Revisions to Existing NIH Grants That Are not Focused on AD/ADRD RFA-AI-25-006, Molecular Mechanisms of Combination Adjuvants (MMCA) (R01, Clinical Trial Not Allowed) 75N93024R00030, NIAID Virology Quality Assurance PA-25-249, NIAID, NIDDK, NIDA, and NIAAA Research Opportunities for New and "At-Risk" Investigators (R01, Clinical Trial Optional) 75N93024R00024, In Vitro Assessments of Antimicrobial Activity PAR-25-099, Planning for Product Development Strategy (R34, Clinical Trial Not Allowed) PAR-25-316, Elucidating Immunometabolic Responses to HIV Infection That Increase TB or HBV Risk (R21, Clinical Trial Not Allowed) PAR-25-315, Elucidating Immunometabolic Responses to HIV Infection That Increase TB or HBV Risk (R01, Clinical Trial Not Allowed) PAR-25-371, Ethical, Legal, and Social Implications (ELSI) Research (R01, Clinical Trial Optional) PAR-25-370, Ethical, Legal, and Social Implications (ELSI) Small Research Grant (R03, Clinical Trial Optional) PAR-25-369, Ethical, Legal, and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21, Clinical Trial Optional) Find other announcements at NIAID Opportunities and Announcements. Send suggestions or comments to deaweb@niaid.nih.gov. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period.  This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107